Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Developing Brand/Generic Labeling “Carve Out” Notification Process

Executive Summary

FDA is developing a process to inform innovators and generic companies when part of a brand drug's labeling can be "carved out" of an ANDA, Associate Counsel for Drugs Elizabeth Dickinson said

You may also be interested in...



Method Of Use Patents Gaining Greater Importance In The Eyes Of Pharma

Large pharmaceutical manufacturers are beginning to see method of use patents as a more valuable piece of their patent portfolios, Gene Logic CEO Mark Gessler said at the Biotechnology Industry Organization/Windhover Partnering Conference for Decision Makers in Washington, D.C. May 17

Method Of Use Patents Gaining Greater Importance In The Eyes Of Pharma

Large pharmaceutical manufacturers are beginning to see method of use patents as a more valuable piece of their patent portfolios, Gene Logic CEO Mark Gessler said at the Biotechnology Industry Organization/Windhover Partnering Conference for Decision Makers in Washington, D.C. May 17

Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect

The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel